EQ-5D™-derived utility values for different levels of migraine severity from a UK sample of migraineurs

Health and Quality of Life Outcomes

Volumn 10, Issue , 2012, Pages

  Stafford, Megan R ^a   Hareendran, Asha ^a   Ng Mak, Daisy S ^b   Insinga, Ralph P ^b   Xu, Ruifeng ^b   Stull, Donald E ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Eq 5d; Health utility; Midas; Migraine; Quality of life

Indexed keywords

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; EQ 5D QUESTIONNAIRE; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; OBSERVATIONAL STUDY; PAIN ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE; UNITED KINGDOM; ANXIETY; COGNITIVE DEFECT; DEPRESSION; DISABILITY; HEALTH SURVEY; HOSPITALIZATION; MIDDLE AGED; PAIN; PSYCHOLOGICAL ASPECT; REPRODUCIBILITY; RETROSPECTIVE STUDY; SOCIOECONOMICS; STANDARD; VISUAL DISORDER;

ADULT; ANXIETY; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DEPRESSION; DISABILITY EVALUATION; FEMALE; GREAT BRITAIN; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PAIN; PAIN MEASUREMENT; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; VISION DISORDERS;

EID: 84861992165     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-10-65     Document Type: Article

References (28)

1. Holroyd KA, Drew JB, Cottrell CK, Romanek KM, Heh V. Impaired functioning and quality of life in severe migraine: the role of catastrophizing and associated symptoms. Cephalalgia 2007, 27:1156-1165. 10.1111/j.1468-2982.2007.01420.x, 2128721, 17784854.
2. Stang P, Cady R, Batenhorst A, Hoffman L. Workplace productivity. A review of the impact of migraine and its treatment. PharmacoEconomics 2001, 19:231-244. 10.2165/00019053-200119030-00002, 11303412.
3. Berg J, Stovner LJ. Cost of migraine and other headaches in Europe. Eur J Neurol 2005, 12(Suppl 1):59-62.
4. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001, 358:1668-1675. 10.1016/S0140-6736(01)06711-3, 11728541.
5. National Institue for Health and Clinical Excellence (NICE) Methods for the development of NICE public health guidance 2009, , second edition, National Institue for Health and Clinical Excellence (NICE).
6. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997, 35:1095-1108. 10.1097/00005650-199711000-00002, 9366889.
7. Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, DePauw S, Denton M, Boyle M. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care 2002, 40:113-128. 10.1097/00005650-200202000-00006, 11802084.
8. EuroQol--a new facility for the measurement of health-related quality of life The EuroQol Group. Health Policy 1990, 16:199-208. EuroQol--a new facility for the measurement of health-related quality of life.
9. Brooks R, Rabin R, de Charro F. The measurement and valuation of health status using EQ-5D: A European perspective 2003, Kluwer Academic Publishers, Dordrecht, Netherlands.
10. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health 2009, 12(Suppl 1):S5-S9.
11. Brown JS, Neumann PJ, Papadopoulos G, Ruoff G, Diamond M, Menzin J. Migraine frequency and health utilities: findings from a multisite survey. Value Health 2008, 11:315-321. 10.1111/j.1524-4733.2007.00246.x, 18380644.
12. Xu R, Insinga RP, Golden W, Hu XH. EuroQol (EQ-5D) health utility scores for patients with migraine. Qual Life Res 2010, 20:601.
13. Luo N, Johnson JA, Shaw JW, Coons SJ. Relative efficiency of the EQ-5D, HUI2, and HUI3 index scores in measuring health burden of chronic medical conditions in a population health survey in the United States. Med Care 2009, 47:53-60. 10.1097/MLR.0b013e31817d92f8, 19106731.
14. Headache Classification Subcommitee of the International Headache Society The International Classification of Headache Disorders 2004, 24. An International Journal of Headache, Cephalalgia, 2, Headache Classification Subcommitee of the International Headache Society.
15. Kind P. EuroQoL Instrument: an index of health-related quality of life. Quality of Life and Pharmacoeconomics in Clinical Trials 1996, Lippincott-Raven, Philadelphia, PA, Spilker B, 2.
16. Lines CR, Vandormael K, Malbecq W. A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients. Pain 2001, 93:185-190. 10.1016/S0304-3959(01)00315-3, 11427330.
17. Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 2000, 88:41-52. 10.1016/S0304-3959(00)00305-5, 11098098.
18. Ekstrom W, Nemeth G, Samnegard E, Dalen N, Tidermark J. Quality of life after a subtrochanteric fracture: a prospective cohort study on 87 elderly patients. Injury 2009, 40:371-376. 10.1016/j.injury.2008.09.010, 19232590.
19. Ekstrom W, Miedel R, Ponzer S, Hedstrom M, Samnegard E, Tidermark J. Quality of life after a stable trochanteric fracture-a prospective cohort study on 148 patients. J Orthop Trauma 2009, 23:39-44. 10.1097/BOT.0b013e318191f5e4, 19104302.
20. Slatkowsky-Christensen B, Mowinckel P, Loge JH, Kvien TK. Health-related quality of life in women with symptomatic hand osteoarthritis: a comparison with rheumatoid arthritis patients, healthy controls, and normative data. Arthritis Rheum 2007, 57:1404-1409. 10.1002/art.23079, 18050180.
21. Kelman L, Tanis D. The relationship between migraine pain and other associated symptoms. Cephalalgia 2006, 26:548-553. 10.1111/j.1468-2982.2006.01075.x, 16674763.
22. Celentano DD, Stewart WF, Linet MS. The relationship of headache symptoms with severity and duration of attacks. J Clin Epidemiol 1990, 43:983-994. 10.1016/0895-4356(90)90082-Z, 2213086.
23. Dowson AJ, Charlesworth B. Review of zolmitriptan and its clinical applications in migraine. Expert Opin Pharmacother 2002, 3:993-1005. 10.1517/14656566.3.7.993, 12083998.
24. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005, 43:203-220. 10.1097/00005650-200503000-00003, 15725977.
25. DeWalt DA, Rothrock N, Yount S, Stone AA. Evaluation of items candidates: the PROMIS qualitative item review. Med Care 2007, 45:S12-21. 10.1097/01.mlr.0000254567.79743.e2, 2810630, 17443114.
26. Stull DE, Leidy NK, Parasuraman B, Chassany O. Optimal recall periods for patient-reported outcomes: challenges and potential solutions. Curr Med Res Opin 2009, 25:929-942. 10.1185/03007990902774765, 19257798.
27. Broderick JE, Stone AA, Calvanese P, Schwartz JE, Turk DC. Recalled pain ratings: a complex and poorly defined task. J Pain 2006, 7:142-149. 10.1016/j.jpain.2005.09.012, 16459280.
28. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia 2003, 23:519-527. 10.1046/j.1468-2982.2003.00568.x, 12950377.